Clinical antifungal efficacy trials in invasive aspergillosis: Consensus standards for trial design and room for improvement

Medical Mycology

Volumn 44, Issue SUPPL. 1, 2006, Pages 289-294

  Nivoix, Y ^a   Fohrer, C ^a   Fornecker, L ^a   Herbrecht, R ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Amphotericin B deoxycholate; Invasive aspergillosis; Voriconazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FUNGUS ANTIGEN; GALACTOMANNAN; PREDNISONE; VORICONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CAUSE OF DEATH; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FACTORIAL ANALYSIS; FUNGUS CULTURE; HEMATOLOGIC MALIGNANCY; HUMAN; MEDICAL EXPERT; MEDICAL RESEARCH; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; RADIOLOGIST; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME;

EID: 33749527894     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780600931986     Document Type: Article

References (29)

1. Herbrecht, R and Denning, DW and Patterson, TF and (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med, 347, pp. 408-415.
2. CornelyOA, MaertensJ, BresnikM, HerbrechtR. Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): A randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood 2005; 106: Abstract 3222.
3. Yeghen, T and Kibbler, CC and Prentice, HG and (2000) Management of invasive pulmonary aspergillosis in hematology patients: A review of 87 consecutive cases at a single institution Clin Infect Dis, 31, pp. 859-868.
4. Ascioglu, S and Rex, JH and de Pauw, B and (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus Clin Infect Dis, 34, pp. 7-14.
5. GreeneRE, SchlammHT, StarkP,. Radiological findings in acute invasive pulmonary aspergillosis: Utility and reliability of halo sign and air-crescent sign for diagnosis and treatment of IPA in high-risk patients. Proceedings of the 13th European Conference on Clinical Microbiology and Infectious Diseases, Glasgow, Scottland, 10-13May2003.
6. Denning, DW and Ribaud, P and Milpied, N and (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis, 34, pp. 563-571.
7. Patterson, TF and Kirkpatrick, WR and White, M and (2000) Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group Medicine (Baltimore), 79, pp. 250-260.
8. Bohme, A and Ruhnke, M and Buchheidt, D and (2003) Treatment of fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Ann Hematol, 82(Suppl. 2), pp. S133-S140.
9. Denning, DW and Kibbler, CC and Barnes, RA. (2003) British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections Lancet Infect Dis, 3, pp. 230-240.
10. Gavalda, J and Ruiz, I. (2003) Guidelines for the treatment of invasive fungal infection. Invasive fungal infection by Candida spp. Invasive Fungal Infection Study Group (MICOMED) and Infection in Transplantation Study Group (GESITRA) of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC) Enferm Infecc Microbiol Clin, 21, pp. 498-508.
11. SFAR, SPILF, SRLF. Management of invasive candidiasis and aspergillosis in adults. Rev Pneumol Clin 2004; 60: 289-293.
12. Slavin, MA and Szer, J and Grigg, AP and (2004) Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections Intern Med J, 34, pp. 192-200.
13. Kuhlman, JE and Fishman, EK and Burch, PA and (1987) Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management Chest, 92, pp. 95-99.
14. Patterson, TF and Boucher, HW and Herbrecht, R and (2005) Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome Clin Infect Dis, 41, pp. 1448-1452.
15. HerbrechtR, JohnsonEM, BaretteM, et al. Longitudinal assessment of galactomannan antigenemia and relationship with outcome in invasive aspergillosis. Advances Against Aspergillosis, San Francisco, 9-11September2004. Med Mycol, 43, S1, Poster Abstract, 61.
16. Herbrecht, R and Letscher-Bru, V and Oprea, C and (2002) Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients J Clin Oncol, 20, pp. 1898-1906.
17. Maertens, J and Verhaegen, J and Lagrou, K and Van Eldere, J and Boogaerts, M. (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation Blood, 97, pp. 1604-1610.
18. Maertens, J and Theunissen, K and Verbeken, E and (2004) Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients Br J Haematol, 126, pp. 852-860.
19. Marr, KA and Balajee, SA and McLaughlin, L and (2004) Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance J Infect Dis, 190, pp. 641-649.
20. Maertens J. Glasmacher A. Herbrecht R. Multicenter, noncomparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis refractory or intolerant to prior therapy: Final results. Proceeding of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, 16-19December2005: Abstract M-954, p. 420.
21. Ribaud, P and Chastang, C and Latge, JP and (1999) Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation Clin Infect Dis, 28, pp. 322-330.
22. Cordonnier, C and Ribaud, P and Herbrecht, R and (2006) Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: A 1-year retrospective study of consecutive patients at French transplantation centers Clin Infect Dis, 42, pp. 955-963.
23. Fukuda, T and Boeckh, M and Carter, RA and (2003) Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning Blood, 102, pp. 827-833.
24. CornelyOA, MaertensJ, BresnikM, Herbrecht, R. Prognosis factors. Advances Against Aspergillosis, Athens, 2006 Med Mycol, Supplement (in preparation).
25. Kullberg, BJ and Sobel, JD and Ruhnke, M and (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial Lancet, 366, pp. 1435-1442.
26. Mora-Duarte, J and Betts, R and Rotstein, C and (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med, 347, pp. 2020-2029.
27. van Burik, JA and Ratanatharathorn, V and Stepan, DE and (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis, 39, pp. 1407-1416.
28. Walsh, TJ and Finberg, RW and Arndt, C and (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group N Engl J Med, 340, pp. 764-771.
29. Walsh, TJ and Pappas, P and Winston, DJ and (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med, 346, pp. 225-234.